Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (11-20 of 383) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Is it safe to treat endometrial carcinoma endoscopically?Ignace Vergote, Frederic Amant, Patrick Neven
Current Opinion in Oncology|October 15, 2005
Choosing between an aromatase inhibitor and tamoxifen in the adjuvant settingLeilani Morales, Patrick Neven, Robert Paridaens
Lancet (London, England)|April 7, 2009
Lymphadenectomy in endometrial cancerFrédéric Amant, Patrick Neven, Ignace Vergote
The New England Journal of Medicine|March 12, 2025
Pembrolizumab in Early-Stage Triple-Negative Breast CancerPatrick Neven, Giuseppe Floris, Christine Desmedt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2025
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trialMarcela Carausu, Patrick Neven, Michail Ignatiadis
The New England Journal of Medicine|October 26, 2012
Anastrozole and fulvestrant in metastatic breast cancerAnneleen Lintermans, Joke Vanderhaegen, Patrick Neven
Breast Cancer Research : BCR|October 3, 2008
A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosisPatrick Neven, Toon Van Gorp, Karen Deraedt
Expert Review of Anticancer Therapy|October 21, 2020
Ribociclib plus fulvestrant in the treatment of breast cancerPatrick Neven, Gabe S Sonke, Guy Jerusalem
European Journal of Cancer (Oxford, England : 1990)|December 18, 2024
Letter re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in BelgiumPatrick Neven, Sileny Han, Didier Verhoeven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathologyLeilani Morales, Robert Paridaens, Dirk Timmerman, et al.
Pageof 39

Showing results (11-20 of 383) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Is it safe to treat endometrial carcinoma endoscopically?Ignace Vergote, Frederic Amant, Patrick Neven
Current Opinion in Oncology|October 15, 2005
Choosing between an aromatase inhibitor and tamoxifen in the adjuvant settingLeilani Morales, Patrick Neven, Robert Paridaens
Lancet (London, England)|April 7, 2009
Lymphadenectomy in endometrial cancerFrédéric Amant, Patrick Neven, Ignace Vergote
The New England Journal of Medicine|March 12, 2025
Pembrolizumab in Early-Stage Triple-Negative Breast CancerPatrick Neven, Giuseppe Floris, Christine Desmedt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2025
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trialMarcela Carausu, Patrick Neven, Michail Ignatiadis
The New England Journal of Medicine|October 26, 2012
Anastrozole and fulvestrant in metastatic breast cancerAnneleen Lintermans, Joke Vanderhaegen, Patrick Neven
Breast Cancer Research : BCR|October 3, 2008
A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosisPatrick Neven, Toon Van Gorp, Karen Deraedt
Expert Review of Anticancer Therapy|October 21, 2020
Ribociclib plus fulvestrant in the treatment of breast cancerPatrick Neven, Gabe S Sonke, Guy Jerusalem
European Journal of Cancer (Oxford, England : 1990)|December 18, 2024
Letter re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in BelgiumPatrick Neven, Sileny Han, Didier Verhoeven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathologyLeilani Morales, Robert Paridaens, Dirk Timmerman, et al.
Pageof 39